<DOC>
	<DOCNO>NCT00003976</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness E7070 treat patient solid tumor .</brief_summary>
	<brief_title>E7070 Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose E7070 patient solid tumor . II . Assess qualitative quantitative toxicity term predictability , duration , intensity , onset , reversibility , dose relationship treatment regimen patient population . III . Determine safe dose phase II evaluation . IV . Assess pharmacokinetics treatment regimen patient . V. Determine possible antitumor activity regimen patient . OUTLINE : This dose escalation study . Patients receive E7070 IV 1 hour every 3 week . Treatment continue least 2 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos E7070 maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : Approximately 30 patient accrue study within 12 month .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm solid tumor amenable standard therapy No brain tumor involvement leptomeningeal disease PATIENT CHARACTERISTICS : Age : 18 70 Performance status : WHO 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Hepatic : Bilirubin le 1.5 mg/dL Transaminases alkaline phosphatase great 2.5 time upper limit normal ( ULN ) ( great 5 time ULN liver metastasis ) Renal : Creatinine great 1.4 mg/dL OR Creatinine clearance least 60 mL/min Other : No active bacterial infection ( e.g. , abscess fistula ) No nonmalignant disease precludes protocol therapy No history alcoholism , drug addiction , psychotic disorder would prevent compliance No glaucoma Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) Endocrine therapy : At least 4 week since prior anticancer hormonal therapy Radiotherapy : At least 4 week since prior radiotherapy ( 6 week extensive radiotherapy ) No concurrent radiotherapy except localized palliation Surgery : Not specify Other : No concurrent investigational drug antitumor drug No sulphonylureas antiarrhythmic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>